DexCom, Inc. (NASDAQ:DXCM) EVP Jacob Steven Leach sold 5,099 shares of the stock in a transaction that occurred on Thursday, June 13th. The stock was sold at an average price of $145.32, for a total transaction of $740,986.68. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Shares of DXCM traded up $1.72 during midday trading on Friday, reaching $148.04. The stock had a trading volume of 1,282,915 shares, compared to its average volume of 1,258,004. DexCom, Inc. has a 1-year low of $90.61 and a 1-year high of $156.16. The firm has a market capitalization of $13.32 billion, a price-to-earnings ratio of 493.47 and a beta of 0.70. The company has a current ratio of 7.18, a quick ratio of 6.75 and a debt-to-equity ratio of 1.57.
DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Wednesday, May 1st. The medical device company reported ($0.05) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.17) by $0.12. DexCom had a negative net margin of 11.51% and a positive return on equity of 8.45%. The business had revenue of $280.50 million for the quarter, compared to analyst estimates of $246.10 million. During the same period last year, the business earned ($0.30) EPS. The company’s revenue was up 52.1% on a year-over-year basis. On average, analysts predict that DexCom, Inc. will post 0.81 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc raised its stake in DexCom by 11.5% during the 3rd quarter. Vanguard Group Inc now owns 7,942,861 shares of the medical device company’s stock worth $1,136,147,000 after acquiring an additional 816,247 shares in the last quarter. Janus Henderson Group PLC raised its stake in DexCom by 16.5% during the 1st quarter. Janus Henderson Group PLC now owns 1,452,485 shares of the medical device company’s stock worth $172,992,000 after acquiring an additional 205,402 shares in the last quarter. Renaissance Technologies LLC raised its stake in DexCom by 29.5% during the 1st quarter. Renaissance Technologies LLC now owns 1,262,141 shares of the medical device company’s stock worth $150,321,000 after acquiring an additional 287,553 shares in the last quarter. Artisan Partners Limited Partnership raised its stake in DexCom by 71.6% during the 1st quarter. Artisan Partners Limited Partnership now owns 1,164,081 shares of the medical device company’s stock worth $138,642,000 after acquiring an additional 485,519 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in DexCom by 6.2% during the 1st quarter. Geode Capital Management LLC now owns 1,106,617 shares of the medical device company’s stock worth $131,717,000 after acquiring an additional 64,486 shares in the last quarter. Institutional investors and hedge funds own 96.50% of the company’s stock.
DXCM has been the subject of a number of research analyst reports. Northland Securities reaffirmed a “hold” rating and set a $125.00 price objective on shares of DexCom in a research report on Thursday, June 6th. TheStreet cut shares of DexCom from a “c” rating to a “d+” rating in a research report on Friday, April 5th. Raymond James decreased their price target on shares of DexCom from $160.00 to $150.00 and set an “outperform” rating for the company in a research report on Thursday, May 2nd. Cowen raised their price target on shares of DexCom from $150.00 to $175.00 and gave the company an “outperform” rating in a research report on Friday, February 22nd. Finally, Zacks Investment Research raised shares of DexCom from a “hold” rating to a “buy” rating and set a $138.00 price target for the company in a research report on Monday, May 6th. Four research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $150.65.
COPYRIGHT VIOLATION WARNING: This story was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2019/06/15/dexcom-inc-nasdaqdxcm-evp-sells-740986-68-in-stock.html.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
See Also: What is an overbought condition?
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.